← All trials
NCT06396026
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2024
- Primary completion
- Mar 30, 2026
- Completion date
- Dec 30, 2027
- First posted
- May 2, 2024
- Last posted
- May 13, 2024
- Enrollment
- 436
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hangzhou Highlightll Pharmaceutical Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.